Muraglitazar

• Description:

  Muraglitazar is a PPAR α/γ dual agonist for the research of type 2 diabetes and associated dyslipidemia. Muraglitazar shows potent activity in vitro at human PPARα (EC50 = 320 nM) and PPARγ (EC50 = 110 nM) [1].

• Product Name Alternative:

  BMS-298585

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H335, H402

• Target:

  PPAR

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/muraglitazar.html

• Purity:

  98.38

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  O=C(O)CN(C(OC1=CC=C(OC)C=C1)=O)CC2=CC=C(OCCC3=C(C)OC(C4=CC=CC=C4)=N3)C=C2

• Molecular Formula:

  C29H28N2O7

• Molecular Weight:

  516.54

• Precautions:

  H315, H319, H335, H402

• References & Citations:

  [1]Buse JB, Rubin CJ, Frederich R, et al. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther. 2005;27 (8) :1181-1195. |[2]Cox SL. Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia. Drugs Today (Barc) . 2005;41 (9) :579-587.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 3

• CAS Number:

  331741-94-7